Actually cydy is not an anomaly. I started watching HEPA a drug that met all it's Nash primary end points mid stage in their phase 2a trial. Shares tanked(July of this year) after the announcement. Just received fast track designation with a shareholder yawn. Their shares are near cydy price, but not as many available their mkt cap is under 100 million. Trial had no SAEs either which should be a new standard if you can get it. They did do the much maligned reverse split to stay nasdaq compliant.

So other promising drugs getting the cold shoulder. One big difference, look at the 10 year chart of HEPA..their stock was once quadruple digits and is now just a bit over a buck. I wonder if anyone is still holding on from that price?(yikes)

This is not a HEPA commercial, just found it interesting that another promising drug company getting similar treatment as cydy and was pointing out similarities.